Core Insights - The National Healthcare Security Administration (NHSA) has officially announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and 19 drugs in the first version of the Commercial Health Insurance Innovative Drug Catalog, effective from January 1, 2026 [1][2][3] Industry Summary - The NHSA has adjusted the drug catalog for the eighth time since its establishment, with a total of 949 new drugs added over the years, and the medical insurance fund has spent over 4.6 trillion RMB on negotiated drugs, driving sales exceeding 6 trillion RMB [1][2] - The new catalog includes 50 first-class innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [3] - The inclusion of drugs for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions, addresses gaps in basic medical insurance coverage [2][3] Company-Specific Updates - Green Leaf Pharmaceutical has successfully included five new products in the NHSA's drug catalog, including MiMeiXin® and ZhanBiJia® [4] - Fuhong Hanlin announced that its product Fuzhuoning® has been included in the NHSA's drug catalog for specific indications [5] - Junshi Biosciences reported that its products Tuoyi® and Junshida® have been successfully included in the NHSA's drug catalog [6] - Innovent Biologics has successfully added seven innovative products to the new NHSA drug catalog, including Daboru® and Xindimian® [6]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 自願性公告 本集團五款新產品成功納入 2025年國家醫保藥品目錄或商保創新藥目錄 瑞百萊® （棕 櫚 酸 帕 利 哌 酮 注 射 液（Ⅱ））是全球首個且唯一實現「首 月 僅 需1針」給 藥 方 案 的 帕 利 哌 酮 長 效 針 劑，在 中 國 獲 批 的 適 應 症 為 用 於 精 神 分 裂 症 急 性 期 和 維 持 期 的 治 療。該 產 品 同 時 也 已 在 美 國 獲 批 上 市。相 較 於 傳 統 的 帕 利 哌 酮 長 效針劑首月需要注射2次的給藥方案（第1天和第8天各注射1次），瑞 百 萊®僅 需 單 次351mg起 始 劑 量 即 可 完 成 初 始 治 療，簡 化 用 ...